Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors

BACKGROUND: Imatinib was the first BCR-ABL tyrosine kinase inhibitor (TKI) approved in the United States for the treatment of patients with chronic myelogenous leukemia and is currently the most prescribed TKI. The impending loss of patent exclusivity for imatinib has the potential to reduce costs f...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am Health Drug Benefits
Hlavní autoři: Bloudek, Lisa M., Makenbaeva, Dinara, Eaddy, Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: Engage Healthcare Communications, LLC 2015
Témata:
Business
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4719136/
https://ncbi.nlm.nih.gov/pubmed/26834933
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky